Risk factors

KVH Industries relies heavily on reselling third-party airtime, predominantly SpaceX Starlink, facing intense margin pressure and intense competition.

LifeMD disclosed material weaknesses in internal control over financial reporting as of December 31, 2025. Over 20 states passed or are considering new artificial intelligence laws affecting operations. Expiration of certain Affordable Care Act provisions at the end of 2025 caused higher insurance premiums.

Accumulated deficit increased to $209.4 million as of December 31, 2025. Third-party supply and patent risks added for LPCN 1154. Tariffs added as a commercialization risk for TLANDO.

Pulmonx added risks covering a new 40 million dollar credit agreement with Perceptive Credit Holdings.

Regulatory review by the SBA threatens Medallion Capital's debenture borrowings and SBIC license operations. Capital raise urgency highlighted by $31.25 million note maturity in February 2026. Management titles updated for key executives across the holding company and Medallion Bank.

Net loss increased to $12.0 million in 2025 with an accumulated deficit reaching $438.7 million. Added specific risks regarding inflation, tariffs, and FDA review impacts.

Restrictive covenants under the Citibank Credit Agreement now limit financing options and asset security.

The company bought out its joint ventures in China from Fosun Industrial for a total consideration of $7.0 million. Direct selling risks continue to dominate operations, sales, and consultant retention.

The company added disclosures covering preferred stock valuation tied to IPM, artificial intelligence deployment in lending, and credit loss scoring model efficacy. Disclosures regarding the NTS divestiture, credit loss forecasting, and SBA loan program dependencies were updated to reflect ongoing operational transitions.

Artificial intelligence and rapid technology changes are newly identified as threats to client retention and competitiveness.

Q32 Bio added new risks covering Nasdaq minimum equity compliance, AI healthcare regulations, and stock option repricing consequences. The company updated financial figures, including NOLs of $423.3 million and $2.4 million in state R&D tax credits.

Rapport Therapeutics added comprehensive privacy and data security risk disclosures reflecting complex state and international regulations.